newsfilter
← Latest News
GlobeNewswire·

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on trackDNL126 Phase 1/2 study enrollment completed, supporting